CBIO
CRESCENT BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$12.36
+4.39%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -13.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -97.0%
- EBITDA
- +86.9%
- EPS
- +55.4%
Three-year CAGR
- Revenue
- +424.9%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +76.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026